Abstract Search

ey0017.11-12 | Pharmacologic Treatment | ESPEYB17

11.12. A randomized, controlled trial of liraglutide for adolescents with obesity

AS Kelly , P Auerbach , M Barrientos-Perez , I Gies , PM Hale , C Marcus , LD Mastrandrea , N Prabhu , S; NN8022-4180 Trial Investigators Arslanian

To read the full abstract: N Engl J Med. 2020;382(22):21172128. doi: https://pubmed.ncbi.nlm.nih.gov/32233338/Kelly et al. randomly assigned (1:1) n =251 obese adolescents (age 12 to <18 years) to receive either liraglutide (3.0 mg), a long-acting glucagon-like peptide-1 agonist, or placebo subcutaneously once daily in addition to lifestyle therapy. Liraglutide w...

2 shares

ey0016.12-5 | Type 2 Diabetes | ESPEYB16

12.5. Liraglutide in children and adolescents with type 2 diabetes

WV Tamborlane , M Barrientos-Perez , U Fainberg , H Frimer-Larsen , M Hafez , PM Hale , MY Jalaludin , M Kovarenko , I Libman , JL Lynch , P Rao , N Shehadeh , S Turan , D Weghuber , T Barrett , I Ellipse Trial

N Engl J Med 2019; 10.1056/NEJMoa1903822.DOI: 10.1056/NEJMoa1903822http://www.ncbi.nlm.nih.gov/pubmed/31034184Summary: In a double-blind, randomized, phase 3 trial, 135 overweight and obese adolescents, aged 10 to 17 years with T2DM, were randomly assigned to receive subcutaneous liraglutide (up to 1.8 mg per day) or placebo, bot...

0 shares

ESPE Yearbook of Paediatric Endocrinology

11.12. A randomized, controlled trial of liraglutide for adolescents with obesity

12.5. Liraglutide in children and adolescents with type 2 diabetes

BiosciAbstracts